Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Stock Rated “Hold” by Wall Street Analysts

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have been assigned a consensus rating of “Hold” from the five research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $53.33.

Separately, Wall Street Zen raised Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, July 5th.

Reviva Pharmaceuticals Stock Performance

RVPH stock opened at $0.50 on Monday. The firm has a 50 day moving average price of $0.49 and a 200-day moving average price of $0.62. Reviva Pharmaceuticals has a 52-week low of $0.26 and a 52-week high of $17.20. The firm has a market capitalization of $6.55 million, a price-to-earnings ratio of -0.27 and a beta of 0.48.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.19. As a group, sell-side analysts forecast that Reviva Pharmaceuticals will post -2.96 earnings per share for the current fiscal year.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. The company’s research is based on its proprietary drug-discovery platform, which is designed to identify medicines that act on multiple serotonin and dopamine receptors.

Reviva’s lead product candidate is brilaroxazine, formerly known as RP5063. Brilaroxazine is an investigational multimodal serotonin-dopamine activity modulator being developed for schizophrenia and other neuropsychiatric and inflammatory conditions, including bipolar depression, major depressive disorder, and certain dementia-related psychoses.